Azenta to restructure Multiomics segment; $11-13M charges, 3 lab closures

Azenta's board approved a restructuring plan on October 5, 2026 involving closure of three North American Multiomics laboratory sites, workforce reductions, and $11–13M in pre-tax charges ($9M asset impairment, $3M severance). The company expects $11M in annualized cost savings once fully implemented by March 31, 2027. Near-term earnings will be pressured by the charges and restructuring costs, but the company is signaling medium-term efficiency gains; the modest scale relative to a diversified life sciences business and the forward-looking savings offset some downside risk.

Azenta is closing three labs and laying off staff to cut costs, taking an $11–13 million charge this year but expecting to save $11 million annually going forward. This hurts current earnings but improves future profitability.